Drugs in diabetes

1. 1. Early insulin initiation in T2DM is associated with prevention of eGFR decline and lower insulin dose requirements. Kesavadev J, Warrier R, Shankar A, David A, Ajai N. A, Sanal G, Thampiraj K, Ramachandran L, Krishnan G, JothydevS.Diabetes. 2019. 68 (S1). 530-P. Read More
2. 2. Consistency and Predictability of Control of Glycemic Variability with U200 (Concentrated r-DNA Human Insulin Premix 30/70-200 IU/mL) in Type 2 Diabetes Mellitus Patients. Thacker H, Kesavadev J, Ingole S. A, Shah A, Jain R. Diabetes. 2019. 68(S1). 2322-PUB. Read More
3. 3. Diabetes duration-based initiation of insulin: impact on clinical outcomes, insulin dosage and quality of life. Kesavadev J, Saboo B, Shankar A, Jothydev K, Ramachandran L, Krishnan G, Jothydev S. Diabetes TechnolTher. 2018. 20(S1). A149- A150. Read More
4. 4. Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Endocr Connect. 2017. 6(8). 748–757. Read More
5. 5. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Int J Gen Med. 2012. 5. 317-322. Read More
6. 6. IDegAsp Improves Glycemic Control with Minimal Hypoglycemia-An Indian Real-World Study in T2D Subjects. Kesavadev J, Saboo B. D, Shankar A, David A, Warrier R, Krishnan NG, Ramachandran L, JothydevS.Diabetes. 2018. 67(S1). 389-P. Read More
7. 7. One-Year Safety and Effectiveness of Insulin Degludec in Patients with Diabetes Mellitus in Routine Clinical Practice in India - TRUST (Tresiba Real-World Use Study). Kesavadev J, Murthy L. S, Saboo B. D, Yalamanchi S. R, Ramanathan B, Gupta S, Chatterjee S, Revanna M, Kasetty H. Diabetes. 2018. 67(S1). 1019-P. Read More
8. 8. The significance of repeated education in correcting insulin injection techniques and improving glycemic control. Kesavadev J, David A, Shankar A, Sowmya J, Ramachandran L, Krishnan G, Jothydev S. Diabetes. 2017. 66 (S).A185-A186.716-P. Read More
9. 9. Liraglutide and Renal Outcomes in Type 2 Diabetes. Mann J. F. E ,Ørsted D. D , Frandsen K. B, Marso S. P, Poulter N. R , Rasmussen S , Tornøe K, Zinman B , Buse J. B , LEADER Steering Committee and Investigators. N Engl J Med. 2017 Aug 31;377 (9):839-848. Link 1 | Link 2
10. 10. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso S. P , Daniels G. H , Frandsen K. B , Kristensen P , Mann J. F. E , Nauck M. A , Nissen S. E , Pocock S , Poulter N. R , Ravn L. S , Steinberg W. M , Stockner M , Zinman B, Bergenstal R.M, Buse J. B , LEADER Steering Committee; LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22. Link 1 | Link 2
11. 11. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green J B, Bethel M. A, Armstrong P.W, Buse J. B, Engel S. S, Garg J, JosseR,Kaufman K. D, Koglin J,'Korn S, Lachin J. M, McGuire D. K, Pencina M. J, Standl E, Stein P.P, Suryawanshi S, Werf F.V de, Peterson E. D, Holman R. R, TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42.
    Link 1 | Link 2
12. 12. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Gopalakrishnan G, JothydevS.DiabetesMetabSyndr. 2015. 9(1). 30-33. Read More
13. 13. Insulin-sparing effect of and Severe Hypoglycemia with Sitagliptin vs. Glimepiride. Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Diabetes. 2015. 64(S1). A604. PO2486. Read More
14. 14. Glycemic Variability in Type 2 Diabetes Correlates with Total Daily Dose of Insulin And Use of Sulfonlyureas. Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Diabetes TechnolTher. 2013. 15(S1). A-66. Link 1 | Link 2
15. 15. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Kesavadev J. Indian J Endocrinol Metab. 2013. 17(S2). S565–S568. Read More
16. 16. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study. Kesavadev J, Joshi S. R. J Assoc Physicians India. 2013. 61(S1). 28-30. Read More
17. 17. Time of Insulin Initiation, Duration of disease and onset of Erectile Dysfunction in Indian men with T2D. Shankar A, Jothydev S, Gopalakrishnan G, Lally J, Kesavadev J. Diabetes. 2013. 62. A697. PO2737. Read More
18. 18. Efficacy and Safety of Liraglutide in 195 Patients with Type 2 Diabetes in India: A Retrospective Analysis. Kesavadev J, Shankar A, Gopalakrishnan G, Veeresh B, JothydevS.Diabetes. 2012. 61(S1). 2403-PO. Read More
19. 19. The usage of basal-plus regimen in the management of diabetes. Kesavadev J. Indian Journal of Clinical Practice (IJCP). Apr 2011.
20. 20. Change in Antihypertensive Medication Dose Following Initiation of Liraglutide in Patients. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Diabetes. 2011. 60(S1) 2357-PO. Link 1 | Link 2 | Link 3
21. 21. Requirement of High Dosage of Insulin in Previous Users of Glibenclamide with Uncontrolled Diabetes. Kesavadev J, Shamsudeen J, Badarudeen S, Simon N. A, Jothydev S. Diabetes. 2009. 58(S1). PO2079. Read More
22. 22. Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study. Kesavadev J, Singh P, Pitle S. U, Bhattacharyya A, Mayya R, Moharana A. K, Pathak A, Kalra S. Diabetes. 2009. 58 (S1). PO2053. Read More
23. 23. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. Kesavadev J, Rasheed SA. J Assoc Physicians India. 2006 Dec;54:951-2. Read More
24. 24. A Study on the Effects of Acarbose in Reducing Post-Prandial Blood Glucose and Achieving HbA1c. Ahammed S, Kumar A, Gopi D. K, Kesavadev J. Diabetes. 2008. 57(S1). 438-P. Read More